363 related articles for article (PubMed ID: 21338257)
1. US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics.
Philip R; Carrington L; Chan M
Bioanalysis; 2011 Feb; 3(4):383-9. PubMed ID: 21338257
[TBL] [Abstract][Full Text] [Related]
2. The role of companion diagnostics in the development and use of mutation-targeted cancer therapies.
Papadopoulos N; Kinzler KW; Vogelstein B
Nat Biotechnol; 2006 Aug; 24(8):985-95. PubMed ID: 16900147
[TBL] [Abstract][Full Text] [Related]
3. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
Tazawa Y
Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
[TBL] [Abstract][Full Text] [Related]
4. Regulatory considerations for companion diagnostic devices.
Lee EY; Shen HC
Biomark Med; 2015; 9(1):67-75. PubMed ID: 25605456
[TBL] [Abstract][Full Text] [Related]
5. What's next after 50 years of psychiatric drug development: an FDA perspective.
Laughren TP
J Clin Psychiatry; 2010 Sep; 71(9):1196-204. PubMed ID: 20923624
[TBL] [Abstract][Full Text] [Related]
6. Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals.
Roscoe DM; Hu YF; Philip R
Expert Rev Mol Diagn; 2015; 15(7):869-80. PubMed ID: 26109316
[TBL] [Abstract][Full Text] [Related]
7. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
Roller ST; Pippins RR; Ngai JW
Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
[TBL] [Abstract][Full Text] [Related]
8. The regulation of home diagnostic tests for genetic disorders: can the FDA deny a premarket application on the basis of the device's social impacts?
Kerouac JD
J Biolaw Bus; 2002; 5(1):34-43. PubMed ID: 12751500
[TBL] [Abstract][Full Text] [Related]
9. FDA perspective on companion diagnostics: an evolving paradigm.
Mansfield EA
Clin Cancer Res; 2014 Mar; 20(6):1453-7. PubMed ID: 24634468
[TBL] [Abstract][Full Text] [Related]
10. [Development of biomarkers for molecular target drugs].
Saijo K; Ishioka C
Nihon Rinsho; 2015 Aug; 73(8):1308-12. PubMed ID: 26281683
[TBL] [Abstract][Full Text] [Related]
11. Best practices for companion diagnostic and therapeutic development: translating between the stakeholders.
Love D; Stratton E; Stocum M
N Biotechnol; 2012 Sep; 29(6):689-94. PubMed ID: 22743138
[TBL] [Abstract][Full Text] [Related]
12. Off-label use of medical devices in radiology: regulatory standards and recent developments.
Smith JJ
J Am Coll Radiol; 2010; 7(2):115-9. PubMed ID: 20142085
[TBL] [Abstract][Full Text] [Related]
13. The history and contemporary challenges of the US Food and Drug Administration.
Borchers AT; Hagie F; Keen CL; Gershwin ME
Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
[TBL] [Abstract][Full Text] [Related]
14. Amendments to general regulations of the Food and Drug Administration. Direct final rule.
Food and Drug Administration, HHS
Fed Regist; 2010 Nov; 75(229):73951-5. PubMed ID: 21121182
[TBL] [Abstract][Full Text] [Related]
15. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
Basile EM; Tolomeo D; Gluck E
Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
[TBL] [Abstract][Full Text] [Related]
16. Regulatory watch: FDA guidance on co-developing investigational drugs.
Nat Rev Drug Discov; 2011 Feb; 10(2):86. PubMed ID: 21283094
[No Abstract] [Full Text] [Related]
17. The FDA's perspective on clinical laboratory devices. The premarket review and evaluation process.
Aziz KJ; Sliva CA; Gutman SI
Am Clin Lab; 1996; 15(1):10-1. PubMed ID: 10163487
[No Abstract] [Full Text] [Related]
18. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
Harapanhalli RS
Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
[TBL] [Abstract][Full Text] [Related]
19. [Diagnostic kits in parasitology: which controls?].
Rossi P
Parassitologia; 2004 Jun; 46(1-2):145-9. PubMed ID: 15305705
[TBL] [Abstract][Full Text] [Related]
20. Targeted medications. New focus on companion tests.
Reinke T
Manag Care; 2012 Feb; 21(2):35-8. PubMed ID: 22393602
[No Abstract] [Full Text] [Related]
[Next] [New Search]
